On January 9, Bradley L. Campbell, currently serving as the Chief Executive Officer of Amicus Therapeutics, Inc. (NASDAQ: FOLD), sold 11,700 shares of the company’s stock. On average, the price of a single share of stock was $11.43, and the sale of those shares resulted in the accumulation of $133,731.00 in revenue. As a result of the sale, the chief executive officer now has direct ownership of 805,536 shares of the company. The current market value of these shares is $9,207,276.48, so the CEO’s total wealth has increased by that amount. If you go to the website of the SEC, you should be able to find a legal file there that details the transaction in greater detail.
Amicus Therapeutics (NASDAQ: FOLD) made public on Monday, November 7, the quarterly financial figures that the company had worked on for the previous few weeks. The company’s pharmaceuticals division reported earnings per share of $0.12, which is $0.07 higher than the average estimate of $0.19. The company’s pharmaceuticals division reported earnings per share of $0.12, which is $0.07 higher than the average estimate of $0.19. The company’s sales for the quarter came in at $81.69 million, which is significantly lower than the consensus projection of $84.55 million made by financial analysts. The net margin and the return on equity for Amicus Therapeutics were negative, with the former being negative by 81.65% and the latter by 123.94%, respectively. According to projections made by experts in equity research, Amicus Therapeutics, Inc. will finish the current fiscal year with a loss of 0.78 cents per share in the revenue generated.
Several research analysts have recently made statements that provide their perspectives on the company they have been analyzing. A recommendation to “buy” the company’s stock was included in the research report on Amicus Therapeutics that StockNews.com published on December 31. The report was about the company. On Tuesday, November 8, Morgan Stanley published an online research report that updated their price objective for Amicus Therapeutics from $14.00 to $15.00 and categorized the stock as “equal weight.” Three market watchers have given a buy rating to the stock, which compares favorably to the recommendation of two industry professionals to maintain the company’s presence in one’s portfolio. The information that can be found on Bloomberg.com suggests that the company is currently regarded as having a recommendation of “Moderate Buy,” and analysts have assigned a price objective of $14.67 on average for the stock.
The price of an individual share of Amicus Therapeutics increased by $0.57 during the trading session that took place on Wednesday, reaching $12.02. There were a total of 2,221,190 transactions, which is significantly higher than the stock’s typical volume of 1,692,727 transactions. The company has a price-to-earnings ratio of -12.45, a market capitalization of $3.38 billion, and a beta value of 0.88. The company’s price-to-earnings ratio is negative. The price of the stock’s moving average over the last 50 days is $11.60; over the last 200 days, it has been trading at $11.22. Over the past year, the share price of Amicus Therapeutics, Inc. has fluctuated between $5.91 and $12.96. The current price of $5.91 is an all-time low. The current ratio is 2.78, the quick ratio is 2.70, and the quick ratio stands alone at 2.70. The debt-to-equity ratio is 2.95.
Within the most recent period, there have been both an increase and a decrease in the amount of FOLD held by hedge funds. Amalgamated Bank increased the proportion of Amicus Therapeutics stock owned by 2.4% during the third quarter. Following the acquisition of an additional 1,060 shares during the preceding quarter, Amalgamated Bank now possesses 44,619 stock held by the biopharmaceutical company. These shares have a combined value of $466,000 and represent the bank’s holdings in the company. During the third quarter, ProShare Advisors LLC increased the amount of Amicus Therapeutics stock owned by 2.3%, bringing its total ownership to 100%. ProShare Advisors LLC now has 53,997 shares of the biopharmaceutical company’s stock in its possession after purchasing an additional 1,211 shares during the most recent quarter. The current market value of the company is 563,000 dollars. Point72 Hong Kong Ltd. increased its holdings in Amicus Therapeutics by 14.9% during the first three months of 2018. Point72 Hong Kong Ltd. now owns a total of 12,685 shares of the stock of the biopharmaceutical business, having purchased an additional 1,646 shares during the most recent quarter to bring the total number of shares owned up to 12,685. At the moment, the market price for these shares is $120,000. Through the second quarter, Xponance Inc. increased the proportion of Amicus Therapeutics shares it owned by 19.2%. Xponance Inc. now has 14,903 shares of the biopharmaceutical company after purchasing an additional 2,396 shares during the most recent quarter. The value of all of Xponance Inc.’s company shares is currently equal to $160,000. And finally, during the period covered by this report, UBS Asset Management Americas Inc. increased the number of shares in its portfolio held by Amicus Therapeutics by 0.9%. UBS Asset Management Americas Inc. now has 271,479 shares in the biopharmaceutical business after purchasing an additional 2,453 shares during the preceding quarter. This brings the company’s total number of shares to 271,453. The price at which these shares are trading on the market now is $2,916,000.
The biotechnology company Amicus Therapeutics, Inc. specializes in the research, development, and commercialization of treatments for unusual medical conditions. Galafold is an oral precision medication that is used for the treatment of people who have been diagnosed with Fabry disease. An amenable galactosidase alpha gene variation is one of the company’s product candidates and commercial medicines, and it is based on the findings of in vitro testing. Galafold was developed by a company called Galafold. Galafold is a medication prescribed to patients clinically diagnosed with Fabry disease.